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In case of an isolated graft to the arch vessel, one should ensure
sufﬁcient space to inﬂate the endoclamp without compromising ce-
rebral perfusion. If uncertain, one should consider cannulating the
brachial or axillary artery to perfuse the brain during the endoclamp
inﬂation.
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Ventricular assist device use for the treatment of acute viral
myocarditis
Veli K. Topkara, MD, Nicholas C. Dang, MD, Fabio Barili, MD, Timothy P. Martens, MD, Isaac George, MD,
Faisal H. Cheema, MD, Hasmet Bardakci, MD, Ali Vefa Ozcan, MD, and Yoshifumi Naka, MD, PhD, New York, NY
Acute viral myocarditis is a rare condition and associ-ated with high mortality due to the rapid developmentof heart failure. Ventricular assist devices (VADs)have become a life-saving approach for patients with
acute viral myocarditis who are otherwise refractory to the aggres-
sive medical therapy.1,2 We reviewed our institutional experience
to evaluate the use of VADs as a treatment option for viral
myocarditis.
Patients and Methods
From January 1995 to March 2005, 11 patients underwent VAD
implantation (left VAD [LVAD] in 10, biventricular assist device
[BIVAD] in 1) for acute viral myocarditis at Columbia-Presbyterian
Medical Center. Patients were evaluated with regards to demo-
graphics, presenting symptoms, histological manifestations, and
electrocardiographic ﬁndings. Outcome variables included bridge-
to-transplantation rate and long-term survival. Data was collected
by retrospective chart review.
Results
The mean age of the population was 33.8  14.2 years. None of
the patients had a previous history of cardiac disease. Prodromal
symptoms preceding the onset of myocarditis included ﬂulike
symptoms, chest pain, syncope, and varicella syndrome (Table 1).
All patients were transferred from outside institutions with diag-
noses of decompensated heart failure complicating acute viral
myocarditis. The diagnosis of viral myocarditis was primarily
based on clinical presentation and histologic ﬁndings and sup-
ported by viral serology and culture. Viral pathogens were isolated
only in 6 of the 11 patients (Table 2). Histologic evidence of acute
myocarditis using the Dallas Criteria was present in 8 patients
(72.7%); only cellular inﬁltrate was found in the remaining pa-
tients.3 At the time of admission to our center, 4 patients were
temporarily supported by either intra-aortic balloon pump (n  3)
or extracorporeal membrane oxygenation (ECMO; n  1). All
patients had electrocardiographic abnormalities including sinus
tachycardia, diffuse nonspeciﬁc repolarization abnormalities, and
bundle branch block.
LVAD was used as the sole support system in 8 patients with
left ventricular failure. BIVAD was temporarily implanted in 2
patients with biventricular failure and was switched to LVAD after
recovery of right ventricular function. One patient was bridged to
transplant using BIVAD alone without the necessity for LVAD.
There were no operative mortalities (0.0%). Nine patients
had postoperative complications including acute renal failure, right
heart failure, reoperation for bleeding, pericardiocentesis for car-
diac tamponade, and sepsis (Table 1). The mean duration of VAD
support was 58.4  91.7 days (range 5-324 days). Four patients
(36.4%) died in-hospital on VAD support with a mean survival of
12  6 postoperative days. Causes of death for these patients
included right heart failure (n  2), sepsis (n  1), and multiorgan
failure (n  1). The mean preoperative LVAD score was signiﬁ-
cantly higher in patients who died compared with those who
survived (6.3  1.3 vs 3.5  1.9, P  .034).4 Of the 7 surviving
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patients, 5 were successfully bridged to cardiac transplantation and
are still alive with a mean posttransplantation survival of 6.5 4.3
years. The remaining 2 patients underwent LVAD explantation
following myocardial recovery.
Discussion
Viral infection of the myocardium occurs not uncommonly, and in
most cases, is of little clinical consequence. However, in rare
instances, it can lead to acute heart failure, followed by severe
hemodynamic compromise and cardiogenic shock. Temporary me-
chanical support by way of ECMO, LVAD, or BIVAD has been
shown to improve survival in these patients either by bridge to
transplantation or bridge to recovery.
The choice of device for mechanical support in these patients
remains controversial. The Thoratec HeartMate (Thoratec Corp,
Pleasanton, CA) LVAD is suitable for explantation in candidates
for myocardial recovery, yet also convenient for long-term support
until a cardiac allograft becomes available. In select patients then,
LVAD alone seems sufﬁcient. In cases of fulminant viral myocar-
ditis with severe left and right ventricular dysfunction, however,
BIVAD may be the more appropriate option. ECMO remains a
suitable alternative, especially in pediatric patients with viral
myocarditis-induced acute heart failure. However, it is not ideal
for extended periods of support.5
To our knowledge, this report is the largest series to date of
patients undergoing VAD insertion for the treatment of acute heart
failure secondary to viral myocarditis. These patients represent a
high-risk group as evidenced by high VAD scores. At the time of
admission, 8 patients were ventilator-dependent and 5 patients
were on mechanical support. Moreover, LVAD score was found to
be a signiﬁcant predictor of mortality.
In summary, we believe that VAD implantation is an effective
therapy in patients with viral myocarditis complicated by acute
heart failure with uni- or biventricular support determined by
severity of illness at presentation. Preoperative risk assessment is
crucial to predict mortality in these patients. Development of new
devices may decrease postoperative complications, facilitate ear-
lier implantation, and improve overall survival in this population.
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TABLE 1. Clinical characteristics of patients with acute viral myocarditis
Patient no. Age Sex Initial symptoms Preoperative support LVAD score* Complications Outcome
1 31 M Varicella — 2 Reop Explant
2 36 F Flulike, chest pain IABP 1 — Transplant
3 36 M Flulike IABP 5 — Transplant
4 29 F Syncope — 6 RHF Expired
5 50 M Chest pain — 5 Reop Expired
6 49 F — — 6 ARF, RHF Expired
7 12 M Flulike, chest pain BIVAD 8 ARF, Sepsis, Reop Expired
8 20 M Flulike — 6 Reop Transplant
9 40 F Flulike — 4 RHF Transplant
10 54 F — IABP, BIVAD 3 Reop Explant
11 16 F Flulike ECMO BIVAD Pericardiocentesis Transplant
LVAD, Left ventricular assist device; IABP, intra-aortic balloon pump; RHF, right heart failure; Reop, reoperation for bleeding; ARF, acute renal failure;
BIVAD, biventricular assist device. *LVAD score out of 10 possible points, directly proportional to postoperative mortality rate.
TABLE 2. Viral pathogens and histology of endomyocardial
biopsies
No. of
patients
Percentage
(%)
Viral pathogens
Epstein-Barr virus 2 18.2
Varicella zoster virus 1 9.1
Inﬂuenza virus 1 9.1
Coxsackie virus 1 9.1
Cytomegalovirus 1 9.1
Histology (Dallas criteria)
Myocyte necrosis and cellular inﬁltrate 8 72.7
Cellular inﬁltrate 3 27.3
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